ArticleFrontiers in immunology2025
Radiomics reveals the biological basis for non-small cell lung cancer prognostic stratification by reflecting tumor immune microenvironment heterogeneity.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Nomogram combining visual imaging and radiomics analysis for distinguishing diffuse hemispheric glioma, H3 G34-mutant from adult-type diffuse high-grade gliomas.Neuroradiology · 2026Article
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- An exploratory study on whole-lung radiomics features from computed tomography for prognostic prediction in non-small cell lung cancer with concurrent chemoradiotherapy.Translational cancer research · 2026Article
- Foundation model-enhanced multimodal radiomics for predicting response to chemo-immunotherapy in advanced lung squamous cell carcinoma.Frontiers in oncology · 2026Article
- Noninvasive immune-inflammatory profiling by ultrasound radiomics for preoperative prediction of central lymph node metastasis in papillary thyroid carcinoma.Frontiers in immunology · 2026Article
- Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature review.Frontiers in immunology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current radiomic non-small cell lung cancer prognostic models predominantly depend on statistical correlations, lacking robust biological validation. This study integrates multi-omics data to develop a preoperative computed tomography (CT) radiomics model, systematically elucidating its biological links to tumor molecular heterogeneity, immune microenvironment, and clinicopathological phenotypes, advancing clinical translation of radiomics. Methods: This retrospective study analyzed 334 surgically resected stage I-IIIA NSCLC patients. Radiomic features were extracted from preoperative contrast-enhanced CT images. LASSO-Cox regression developed the Rad-score. Cross-cohort validation applied fixed feature thresholds. Integrated gene set enrichment analysis, differential gene expression, and immune microenvironment analyses revealed biological disparities between radiomics risk-stratified groups. Integrated clinicopathological data explored radiomics risk stratification and clinical phenotype associations, constructing a tripartite cross-scale explanatory framework of radiomics-genomics-clinical phenotypes. Results: The Rad-score demonstrated robust prognostic stratification capacity across the training, internal validation, and external validation cohorts. Gene set enrichment analysis revealed significant enrichment of tumor invasion and proliferation-related pathways-including hypoxia, TNFA-NF-κB signaling, inflammatory response, and angiogenesis-in the high-risk group. Differential gene analysis further identified marked disparities in cell cycle regulation, DNA repair, and platinum resistance between risk groups. Immune microenvironment profiling showed significantly reduced immune scores and decreased proportions of naive B cells in high-risk patients, indicating impaired immune activity. At the macro level, the high-risk group exhibited stronger inflammatory responses, more aggressive clinicopathological phenotypes, and poorer nutritional status, mutually validated by micro-genomic characteristics. Conclusion: This study demonstrates that radiomics can non-invasively reveal tumor molecular heterogeneity and immune microenvironment characteristics, elucidating direct associations between imaging features and tumor biological behavior. These findings provide a critical theoretical foundation for the clinical translation of radiomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.